About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05992337

New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.

Early detection and thus rapid therapy of cardiotoxicity related to chemotherapy are essential for restoring cardiovascular function. The complete recovery of the cardiovascular system decreases with ...

Lead sponsor: Cardiology Prague•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Robert Petr, MD.

CONTACT

+420 233 336 334 robert.petr81@gmail.com

Sponsors

Lead Sponsor

Cardiology Prague

Collaborators

BioVendor LM
Oncology Center Medicon

The most effective approach to minimizing the consequences of cardiotoxicity of oncological treatment is its early identification, adjustment of oncological treatment (change of procedure, dose, drugs), and immediate initiation of cardiovascular therapy. However, the current standard for monitoring the cardiovascular system in cancer patients identifies cardiotoxicity only if functional impairment has already occurred, which precludes any chance of effective prevention. The aim of the project is to identify new biomarkers for the early detection of the cardiotoxic effect of chemotherapy in women with breast cancer.

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Breast cancer
•Chemotherapy with a known cardiotoxic side effect

Exclusion Criteria

•Known cardiovascular disease

Related studies

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

NCT07528586 · Cardiotoxicity, Anthracycline-induced Cardiotoxicity

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730 · Cardiotoxicity, Heart Failure, and more

Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age

NCT07382141 · Cardiotoxicity

RECRUITINGPhase 2

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)

NCT06313203 · Intrahepatic Cholangiocarcinoma, Chemotherapy Effect

RECRUITINGPhase 2

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

NCT06510010 · Chemotherapy Effect

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 16, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment200

Start dateSep 2021

Last updatedAug 16, 2023

Condition

Cardiotoxicity Chemotherapy Effect Chemotherapy Induced Systolic Dysfunction

Locations shown

Cardiology Prague Ltd

Prague

Oncology Center Medicon

Prague

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 16, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions